The nuclear factor-κB pathway down-regulates expression of the NKG2D ligand H60a in vitro: implications for use of nuclear factor-κB inhibitors in cancer therapy
Version of Record online: 23 APR 2013
© 2013 Blackwell Publishing Ltd
Volume 139, Issue 2, pages 265–274, June 2013
How to Cite
Peinado, C., Kang, X., Hardamon, C., Arora, S., Mah, S., Zhang, H., Ngolab, J. and Bui, J. D. (2013), The nuclear factor-κB pathway down-regulates expression of the NKG2D ligand H60a in vitro: implications for use of nuclear factor-κB inhibitors in cancer therapy. Immunology, 139: 265–274. doi: 10.1111/imm.12080
- Issue online: 23 APR 2013
- Version of Record online: 23 APR 2013
- Accepted manuscript online: 28 JAN 2013 12:30AM EST
- Manuscript Accepted: 22 JAN 2013
- Manuscript Revised: 15 JAN 2013
- Manuscript Received: 20 AUG 2012
- American Cancer Society. Grant Number: ACS-IRG #70-002
- Cancer Research Coordinating Committee. Grant Number: 6-444951-34384
- NIH. Grant Numbers: CA128893, CA157885
Figure S1. Microarray analysis of H60a-hi and H60a-lo MCA sarcoma cell lines shows that A20 (tumor necrosis factor, alpha-induced protein 3) is expressed highly in some H60a-hi cell lines but is poorly expressed in all H60a-lo cell lines.
Figure S2. Measurement of A20 by qRTPCR shows a trend for H60a-hi cells to have more A20 than H60a-lo cells.
Figure S3. Inhibition of the NF-kB pathway by slz and BAY-11-7085 induced H60a expression.
Figure S4. TNF stimulation does not alter H60a levels significantly. A20 is induced at early timepoints.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.